L04AC Interleukin inhibitors Interleukin inhibitors 白细胞介素抑制剂 白血球介素抑制劑 L4
Source: Wikipedia · CC BY-SA 4.0 Fuente: Wikipedia · CC BY-SA 4.0 · nombre de respaldo (en) 来源:维基百科 · CC BY-SA 4.0 來源:維基百科(中文轉繁體) · CC BY-SA 4.0 (derived zh-Hant)
ATC level L4 · Search this class · Consumer categories
Active ingredients in this class
37 active ingredients 37 principios activos 37 个活性成分 37 個有效成分
The market codes after a status are the markets where that status is recorded (same codes as the product tables). An ingredient can be on sale in one market and withdrawn in another; that is a record fact, not a safety judgement.
- 乌司奴单抗
L04ACactiveCN - 佩索利单抗
L04ACactiveCN - 依奇珠单抗
L04ACactiveCN - 利纳西普
L04ACactiveCN - 古塞奇尤单抗
L04ACactiveCN - Siltuximab
L04AC11activeUS·GB·CA·AU·SG·CN·ES·TW·EUunknownAU·HK - Secukinumab
L04AC10discontinuedES·MXactiveUS·GB·CA·AU·SG·CN·ES·TW·EUunknownAU·HK - 夫那奇珠单抗
L04ACactiveCN - Basiliximab
L04AC02discontinuedMXactiveUS·GB·CA·SG·CN·TW·EUunknownAU·HK - 布罗利尤单抗
L04ACactiveCN - 托珠单抗
L04ACactiveCN - 抗CD25人源化单克隆抗体
L04ACactiveCN - 替瑞奇珠单抗
L04ACactiveCN - 比奇珠单抗
L04ACactiveCN - 萨特利珠单抗
L04ACactiveCN - 赛立奇单抗
L04ACactiveCN - 阿那白滞素
L04ACactiveCN - Anakinra
L04AC03activeUS·GB·CA·AU·ES·EUunknownAU - Basilixmab
L04AC02discontinuedESactiveES - Bimekizumab
L04AC21activeUS·GB·CA·AU·ES·MX·TW·EUunknownAU·HK - Brodalumab
L04AC12activeUS·GB·CA·ES·TW·EUunknownHK - Canakinumab
L04AC08withdrawnESdiscontinuedCAactiveUS·GB·CA·ES·TW·EUunknownAU·MX·HK - Daclizumab
L04AC01withdrawnEUdiscontinuedCAactiveGB - Daclizumab Beta
L04AC01withdrawnEUdiscontinuedCA - Espesolimab
L04AC22activeES - Guselkumab
L04AC16discontinuedMXactiveUS·GB·CA·AU·SG·ES·MX·TW·EUunknownAU·HK - Icotrokinra Containing Product
L04AC28discontinuedES - Ixekizumab
L04AC13discontinuedMXactiveUS·GB·CA·AU·SG·ES·TW·EUunknownAU·HK - Mirikizumab
L04AC24discontinuedESactiveUS·GB·CA·ES·MX·TW·EUunknownAU - Rilonacept
L04AC04withdrawnEUactiveUS - Risankizumab
L04AC18discontinuedCA·ES·MXactiveUS·GB·CA·AU·SG·ES·TW·EUunknownAU·HK - Sarilumab
L04AC14discontinuedCA·ESactiveUS·GB·CA·ES·EUunknownHK - Satralizumab
L04AC19activeUS·GB·CA·SG·ES·TW·EUunknownAU·HK - Spesolimab
L04AC22activeUS·GB·CA·SG·TW·EUunknownAU·HK - Tildrakizumab
L04AC17discontinuedESactiveUS·GB·CA·AU·SG·ES·MX·TW·EUunknownAU·HK - Tocilizumab
L04AC07discontinuedES·MXactiveUS·GB·CA·AU·SG·ES·TW·EUunknownAU·MX·HK - Ustekinumab
L04AC05withdrawnES·EUdiscontinuedES·MXactiveUS·GB·CA·AU·SG·ES·MX·TW·EUunknownAU·MX·HK
By dosage form, across markets
An ATC class only groups medicines by similar pharmacology/chemistry — it does not mean they are interchangeable. A different ingredient, dosage form, release mechanism or strength is not interchangeable.
Only ingredients with a recorded ATC class are listed (6,009 of 12,637).
Class names are editorial translations or come from Wikipedia (CC BY-SA 4.0) / Wikidata (CC0); each ATC page lists the exact source, licence and link for every language. Only the ATC code and the WHO hierarchy are authoritative.
Notes & licences
Status badges summarise the product records held for each ingredient (active / discontinued / withdrawn / unknown), and the market codes after each badge show where that status is recorded. Only some registers publish a status column: CA, ES and MX do; AU and HK have no status column and are recorded as unknown; CN, US, GB, TW and SG records are on the register and marked active.
Class and category names are editorial or AI-assisted translations; only the ATC code and the WHO hierarchy are authoritative.
ATC codes and hierarchy reference the WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (copyright WHOCC; the index itself is not reproduced). Ingredient/strength facts come from the regulator records listed on About.